Regeneron: unfavourable legal decision
(CercleFinance.com) - The clinical stage immuno-oncology firm which develops innovative treatments based on bispecific antibodies (Biclonics®), Merus NV, said this Thursday that the United States Court of Appeals for the Federal Circuit had rejected a petition by Regeneron Pharmaceutical.
The American pharmaceutical group had applied for a new en banc hearing to reconsider the legal decision affirming that Regeneron engaged in inequitable conduct before the United States Patent and Trademark Office during the procedure to obtain U.S. Patent No. 8,502,018 (patent '018) named 'Methods of Modifying Eukaryotic Cells'.
Regeneron filed a complaint against Merus in March 2014 alleging that it infringed one or more claims in the '018 patent. Merus filed counterclaims seeking, among other things, a declaratory judgment that Merus did not infringe the said patent, that it was invalid and a declaratory judgment of unenforceability of the '018 patent on the basis that the patent was procured by inequitable conduct.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The American pharmaceutical group had applied for a new en banc hearing to reconsider the legal decision affirming that Regeneron engaged in inequitable conduct before the United States Patent and Trademark Office during the procedure to obtain U.S. Patent No. 8,502,018 (patent '018) named 'Methods of Modifying Eukaryotic Cells'.
Regeneron filed a complaint against Merus in March 2014 alleging that it infringed one or more claims in the '018 patent. Merus filed counterclaims seeking, among other things, a declaratory judgment that Merus did not infringe the said patent, that it was invalid and a declaratory judgment of unenforceability of the '018 patent on the basis that the patent was procured by inequitable conduct.
Copyright (c) 2017 CercleFinance.com. All rights reserved.